Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-19
    E.g., 2018-04-19

Archive Search


255783 items
3:47 PM, Apr 19, 2018  |  BC Extra | Preclinical News

Synthetic tattoo could detect asymptomatic cancer

A team from ETH Zurich developed a synthetic cellular sensor that darkens a patient's skin in the presence of hypercalcemia -- a disorder associated with many cancers that often arises before signs of cancer --...
2:45 PM, Apr 19, 2018  |  BC Extra | Company News

Novartis reports first Kymriah sales, Cosentyx miss

Novartis AG (NYSE:NVS; SIX:NOVN) reported $580 million in 1Q18 sales of autoimmune drug Cosentyx secukinumab, shy of analysts' $635 million consensus estimate. The pharma also reported for the first time sales of CAR T therapy...
1:43 PM, Apr 19, 2018  |  BC Extra | Company News

Panel: Risk/benefit favorable for GW's Epidiolex

An FDA advisory committee voted 13-0 on Thursday that the benefit-risk profile of Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) was favorable to treat seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome ages 2...
1:27 PM, Apr 19, 2018  |  BC Extra | Financial News

Apellis raises $140.3M in follow-on

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...
1:26 PM, Apr 19, 2018  |  BC Extra | Company News

Target ALS, partners launch biomarker study

Target ALS Foundation is partnering with the Muscular Dystrophy Association (MDA), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis. The study will seek to...
12:57 PM, Apr 19, 2018  |  BC Extra | Politics & Policy

FDA to ease pharma-payer communications

FDA will release a final guidance "shortly" on communication of pharmacoeconomic information between manufacturers and “sophisticated intermediaries” such as PBMs and hospital-based pharmacy and therapeutics committees, FDA Commissioner Scott Gottlieb said Thursday. He did not...
12:17 PM, Apr 19, 2018  |  BC Innovations | Emerging Company Profile

Engine power

Engine Biosciences Pte. Ltd. is marrying a CRISPR-Cas9 genetic perturbation screen with machine learning to delineate how combinations of genes contribute to disease phenotypes and thereby identify novel targets for a range of diseases. The company...
11:24 AM, Apr 19, 2018  |  BC Extra | Preclinical News

Increased ubiquitination of EZH2 or ALK for cancer therapies

Papers published in Cell Reports and Journal of Medicinal Chemistry suggest that targeted degradation by increasing ubiquitination of proteins that promote cancer could be a more complete strategy to treat cancer than catalytic inhibition. As increased...
11:03 AM, Apr 19, 2018  |  BC Extra | Company News

Shire rejects third Takeda bid, Allergan wavers

Shire plc (LSE:SHP; NASDAQ:SHPG) said Thursday its board has unanimously rejected three separate takeout offers from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), culminating at the most recent bid valued at £44 billion ($62.7 billion) in which...
10:40 AM, Apr 19, 2018  |  BC Extra | Financial News

BenevolentAI raises $115M

BenevolentAI (London, U.K.) raised $115 million in a financing round that drew participation from 50 new and existing investors, including existing investor Woodford Investment Management. Most of the investors were U.S.-based. BenevolentAI’s Judgment Augmented Cognition platform...